For muscle-invasive bladder cancer with predominant (>90%) squamous differentiation, would you consider cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy or upfront surgery?

While muscle-invasive bladder cancer (MIBC) patients with a minor variant histology component are treated similarly to conventional urothelial carcinoma (i.e., neoadjuvant cisplatin-based combination followed by surgery), there are no definitive data to guide the perioperative systemic therapy of th...